Apomorphine: An underutilized therapy for Parkinson's disease
Identifieur interne : 004B41 ( Main/Exploration ); précédent : 004B40; suivant : 004B42Apomorphine: An underutilized therapy for Parkinson's disease
Auteurs : Werner Poewe [Autriche] ; Gregor K. Wenning [Autriche]Source :
- Movement Disorders [ 0885-3185 ] ; 2000-09.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
- Agonist, Antiparkinson Agents (administration & dosage), Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Antiparkinson agent, Apomorphine, Apomorphine (administration & dosage), Apomorphine (adverse effects), Apomorphine (therapeutic use), Chemotherapy, Complication, Controlled Clinical Trials as Topic, Dopamine agonist, Dopamine receptor, Drug Therapy, Combination, Dyskinesia, Dyskinesia, Drug-Induced (drug therapy), Dyskinesia, Drug-Induced (prevention & control), Dyskinesias, Follow-Up Studies, Human, Humans, Indication, Infusions, Intravenous, Injections, Subcutaneous, Motor fluctuations, Parkinson Disease (drug therapy), Parkinson Disease (physiopathology), Parkinson disease, Parkinson's disease, Subcutaneous administration, Toxicity, Treatment, Treatment Outcome.
- MESH :
- chemical , administration & dosage : Antiparkinson Agents, Apomorphine.
- chemical , adverse effects : Antiparkinson Agents, Apomorphine.
- chemical , therapeutic use : Antiparkinson Agents, Apomorphine.
- drug therapy : Dyskinesia, Drug-Induced, Parkinson Disease.
- physiopathology : Parkinson Disease.
- prevention & control : Dyskinesia, Drug-Induced.
- Controlled Clinical Trials as Topic, Drug Therapy, Combination, Follow-Up Studies, Humans, Infusions, Intravenous, Injections, Subcutaneous, Treatment Outcome.
Abstract
Apomorphine was the first dopaminergic drug ever used to treat symptoms of Parkinson's disease. While powerful antiparkinsonian effects had been observed as early as 1951, the potential of treating fluctuating Parkinson's disease by subcutaneous administration of apomorphine has only recently become the subject of systematic study. A number of small scale clinical trials have unequivocally shown that intermittent subcutaneous apomorphine injections produce antiparkinsonian benefit close if not identical to that seen with levodopa and that apomorphine rescue injections can reliably revert off‐periods even in patients with complex on–off motor swings. Continuous subcutaneous apomorphine infusions can reduce daily off‐time by more than 50% in this group of patients, which appears to be a stronger effect than that generally seen with add‐on therapy with oral dopamine agonists or COMT inhibitors. Extended follow‐up studies of up to 8 years have demonstrated long‐term persistence of apomorphine efficacy. In addition, there is convincing clinical evidence that monotherapy with continuous subcutaneous apomorphine infusions is associated with marked reductions of preexisting levodopa‐induced dyskinesias. The main side effects of subcutaneous apomorphine treatment are related to cutaneous tolerability problems, whereas sedation and psychiatric complications play a lesser role. Given the marked degree of efficacy of subcutaneous apomorphine treatment in fluctuating Parkinson's disease, this approach seems to deserve more widespread clinical use.
Url:
DOI: 10.1002/1531-8257(200009)15:5<789::AID-MDS1005>3.0.CO;2-H
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001698
- to stream Istex, to step Curation: 001698
- to stream Istex, to step Checkpoint: 003342
- to stream Main, to step Merge: 007439
- to stream PascalFrancis, to step Corpus: 002B34
- to stream PascalFrancis, to step Curation: 000187
- to stream PascalFrancis, to step Checkpoint: 002C57
- to stream Main, to step Merge: 007649
- to stream PubMed, to step Corpus: 003F24
- to stream PubMed, to step Curation: 003F24
- to stream PubMed, to step Checkpoint: 004042
- to stream Ncbi, to step Merge: 000327
- to stream Ncbi, to step Curation: 000327
- to stream Ncbi, to step Checkpoint: 000327
- to stream Main, to step Merge: 007185
- to stream Main, to step Curation: 004B41
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Apomorphine: An underutilized therapy for Parkinson's disease</title>
<author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<affiliation><country>Autriche</country>
<placeName><settlement type="city">Innsbruck</settlement>
<region nuts="2" type="region">Tyrol (Land)</region>
</placeName>
<orgName type="university">Université de médecine d'Innsbruck</orgName>
</affiliation>
</author>
<author><name sortKey="Wenning, Gregor K" sort="Wenning, Gregor K" uniqKey="Wenning G" first="Gregor K." last="Wenning">Gregor K. Wenning</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:D1BB95239F6DB7EB5C3429018B5A2E23389A1705</idno>
<date when="2000" year="2000">2000</date>
<idno type="doi">10.1002/1531-8257(200009)15:5<789::AID-MDS1005>3.0.CO;2-H</idno>
<idno type="url">https://api.istex.fr/document/D1BB95239F6DB7EB5C3429018B5A2E23389A1705/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001698</idno>
<idno type="wicri:Area/Istex/Curation">001698</idno>
<idno type="wicri:Area/Istex/Checkpoint">003342</idno>
<idno type="wicri:doubleKey">0885-3185:2000:Poewe W:apomorphine:an:underutilized</idno>
<idno type="wicri:Area/Main/Merge">007439</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:00-0481439</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002B34</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000187</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">002C57</idno>
<idno type="wicri:doubleKey">0885-3185:2000:Poewe W:apomorphine:an:underutilized</idno>
<idno type="wicri:Area/Main/Merge">007649</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:11009181</idno>
<idno type="wicri:Area/PubMed/Corpus">003F24</idno>
<idno type="wicri:Area/PubMed/Curation">003F24</idno>
<idno type="wicri:Area/PubMed/Checkpoint">004042</idno>
<idno type="wicri:Area/Ncbi/Merge">000327</idno>
<idno type="wicri:Area/Ncbi/Curation">000327</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000327</idno>
<idno type="wicri:doubleKey">0885-3185:2000:Poewe W:apomorphine:an:underutilized</idno>
<idno type="wicri:Area/Main/Merge">007185</idno>
<idno type="wicri:Area/Main/Curation">004B41</idno>
<idno type="wicri:Area/Main/Exploration">004B41</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Apomorphine: An underutilized therapy for Parkinson's disease</title>
<author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<affiliation wicri:level="1"><country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Neurology, University Hospital Innsbruck, Innsbruck</wicri:regionArea>
<wicri:noRegion>Innsbruck</wicri:noRegion>
<placeName><settlement type="city">Innsbruck</settlement>
<region nuts="2" type="region">Tyrol (Land)</region>
</placeName>
<orgName type="university">Université de médecine d'Innsbruck</orgName>
</affiliation>
</author>
<author><name sortKey="Wenning, Gregor K" sort="Wenning, Gregor K" uniqKey="Wenning G" first="Gregor K." last="Wenning">Gregor K. Wenning</name>
<affiliation wicri:level="1"><country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Neurology, University Hospital Innsbruck, Innsbruck</wicri:regionArea>
<wicri:noRegion>Innsbruck</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>John Wiley & Sons, Inc.</publisher>
<pubPlace>New York</pubPlace>
<date type="published" when="2000-09">2000-09</date>
<biblScope unit="vol">15</biblScope>
<biblScope unit="issue">5</biblScope>
<biblScope unit="page" from="789">789</biblScope>
<biblScope unit="page" to="794">794</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">D1BB95239F6DB7EB5C3429018B5A2E23389A1705</idno>
<idno type="DOI">10.1002/1531-8257(200009)15:5<789::AID-MDS1005>3.0.CO;2-H</idno>
<idno type="ArticleID">MDS1005</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Agonist</term>
<term>Antiparkinson Agents (administration & dosage)</term>
<term>Antiparkinson Agents (adverse effects)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Antiparkinson agent</term>
<term>Apomorphine</term>
<term>Apomorphine (administration & dosage)</term>
<term>Apomorphine (adverse effects)</term>
<term>Apomorphine (therapeutic use)</term>
<term>Chemotherapy</term>
<term>Complication</term>
<term>Controlled Clinical Trials as Topic</term>
<term>Dopamine agonist</term>
<term>Dopamine receptor</term>
<term>Drug Therapy, Combination</term>
<term>Dyskinesia</term>
<term>Dyskinesia, Drug-Induced (drug therapy)</term>
<term>Dyskinesia, Drug-Induced (prevention & control)</term>
<term>Dyskinesias</term>
<term>Follow-Up Studies</term>
<term>Human</term>
<term>Humans</term>
<term>Indication</term>
<term>Infusions, Intravenous</term>
<term>Injections, Subcutaneous</term>
<term>Motor fluctuations</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (physiopathology)</term>
<term>Parkinson disease</term>
<term>Parkinson's disease</term>
<term>Subcutaneous administration</term>
<term>Toxicity</term>
<term>Treatment</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Apomorphine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Apomorphine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Apomorphine</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dyskinesia, Drug-Induced</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Dyskinesia, Drug-Induced</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Controlled Clinical Trials as Topic</term>
<term>Drug Therapy, Combination</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Infusions, Intravenous</term>
<term>Injections, Subcutaneous</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Agoniste</term>
<term>Antiparkinsonien</term>
<term>Apomorphine</term>
<term>Chimiothérapie</term>
<term>Complication</term>
<term>Dyskinésie</term>
<term>Fluctuation motrice</term>
<term>Homme</term>
<term>Indication</term>
<term>Parkinson maladie</term>
<term>Récepteur dopaminergique</term>
<term>Stimulant dopaminergique</term>
<term>Toxicité</term>
<term>Traitement</term>
<term>Voie souscutanée</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Apomorphine was the first dopaminergic drug ever used to treat symptoms of Parkinson's disease. While powerful antiparkinsonian effects had been observed as early as 1951, the potential of treating fluctuating Parkinson's disease by subcutaneous administration of apomorphine has only recently become the subject of systematic study. A number of small scale clinical trials have unequivocally shown that intermittent subcutaneous apomorphine injections produce antiparkinsonian benefit close if not identical to that seen with levodopa and that apomorphine rescue injections can reliably revert off‐periods even in patients with complex on–off motor swings. Continuous subcutaneous apomorphine infusions can reduce daily off‐time by more than 50% in this group of patients, which appears to be a stronger effect than that generally seen with add‐on therapy with oral dopamine agonists or COMT inhibitors. Extended follow‐up studies of up to 8 years have demonstrated long‐term persistence of apomorphine efficacy. In addition, there is convincing clinical evidence that monotherapy with continuous subcutaneous apomorphine infusions is associated with marked reductions of preexisting levodopa‐induced dyskinesias. The main side effects of subcutaneous apomorphine treatment are related to cutaneous tolerability problems, whereas sedation and psychiatric complications play a lesser role. Given the marked degree of efficacy of subcutaneous apomorphine treatment in fluctuating Parkinson's disease, this approach seems to deserve more widespread clinical use.</div>
</front>
</TEI>
<affiliations><list><country><li>Autriche</li>
</country>
<region><li>Tyrol (Land)</li>
</region>
<settlement><li>Innsbruck</li>
</settlement>
<orgName><li>Université de médecine d'Innsbruck</li>
</orgName>
</list>
<tree><country name="Autriche"><region name="Tyrol (Land)"><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
</region>
<name sortKey="Wenning, Gregor K" sort="Wenning, Gregor K" uniqKey="Wenning G" first="Gregor K." last="Wenning">Gregor K. Wenning</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004B41 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004B41 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:D1BB95239F6DB7EB5C3429018B5A2E23389A1705 |texte= Apomorphine: An underutilized therapy for Parkinson's disease }}
![]() | This area was generated with Dilib version V0.6.23. | ![]() |